Suven Life Sciences said it has been granted a product patent by Brazil and Eurasia each for a new chemical entity (NCE) used in the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2023 and 2034, respectively, the company said in a BSE filing. Venkat Jasti, CEO, Suven Life, said: “We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.” The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer′s disease, attention deficit hyperactivity disorder (ADHD), Huntington′s disease, Parkinson′s and schizophrenia, it added.